Outcomes of Drug-Based and Surgical Treatments for Primary Aldosteronism

Olivier Steichen (1, 2, 3) , Aurelien Lorthioir (4, 5) , Franck Zinzindohoue (6, 4) , Pierre-François Plouin (4, 6) , Laurence Amar (4, 6)

1 LIMICS - Laboratoire d'Informatique Médicale et Ingénierie des Connaissances en e-Santé
2 CHU Tenon [AP-HP]
3 UPMC - Université Pierre et Marie Curie - Paris 6
4 UPD5 Médecine - Université Paris Descartes - Faculté de Médecine
5 Centre d'Investigation Clinique - Epidemiologie Clinique/essais Cliniques [CHU HEGP]
6 HEGP - Hôpital Européen Georges Pompidou [APHP]

Treatments for primary aldosteronism (PA) aim to correct or prevent the deleterious consequences of hyperaldosteronism: hypertension, hypokalemia, and direct target organ damage. Patients with unilateral PA considered fit for surgery can undergo laparoscopic adrenalectomy, which significantly decreases blood pressure (BP) and medications in most cases and cures hypertension in about 40%. Mineralocorticoid receptor antagonists (MRA) are used to treat patients with bilateral PA and those with unilateral PA if surgery is not possible or not desired. Spironolactone is more potent than eplerenone, but high doses are poorly tolerated in men. MRA can be replaced or complemented with epithelial sodium channel blockers, such as amiloride. Thiazide diuretics and calcium channel blockers are used when the first-line drugs are insufficient to control BP. Dietary sodium restriction should be implemented in all cases because the deleterious consequences of hyperaldosteronism are dependent on salt loading. Several studies comparing the results of surgery and MRA have reported no differences in terms of BP, serum potassium concentration, or cardiovascular and kidney outcomes, although the benefits of treatment tend to be observed sooner with surgery. Patients with PA display relative glomerular hyperfiltration, which is reversed by specific treatment, revealing CKD in 30% of patients. However, further kidney damage is lessened by the treatment of PA.

Mots clés: Hyperaldosteronism; Adrenalectomy; Mineralocorticoid receptor antagonists; Epithelial sodium channel blockers; Chronic kidney disease

Domaines: Urologie et Néphrologie

Olivier Steichen, Aurelien Lorthioir, Franck Zinzindohoue, Pierre-François Plouin, Laurence Amar. Outcomes of Drug-Based and Surgical Treatments for Primary Aldosteronism. Advances in Chronic Kidney Disease, 2015, 22 (3), pp.196-203. ⟨10.1053/j.ackd.2014.10.003⟩. ⟨hal-01153360⟩